Furman RR - Search Results

1

Acalabrutinib in treatment-naive chronic lymphocytic leukemia.

Byrd JC, Woyach JA, Furman RR, Martin P, O'Brien S, Brown JR, Stephens DM, Barrientos JC, Devereux S, Hillmen P, Pagel JM, Hamdy A, Izumi R, Patel P, Wang MH, Jain N, Wierda WG. Byrd JC, et al. Among authors: furman rr. Blood. 2021 Jun 17;137(24):3327-3338. doi: 10.1182/blood.2020009617. Blood. 2021. PMID: 33786588 Free PMC article. Clinical Trial.

2

Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells.

Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Furman RR, et al. J Immunol. 2000 Feb 15;164(4):2200-6. doi: 10.4049/jimmunol.164.4.2200. J Immunol. 2000. PMID: 10657675

3

Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma.

Martin P, Furman RR, Coleman M, Leonard JP. Martin P, et al. Among authors: furman rr. Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5636s-5642s. doi: 10.1158/1078-0432.CCR-07-1085. Clin Cancer Res. 2007. PMID: 17875800 Review.

4

Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma.

Martin P, Furman RR, Ruan J, Elstrom R, Barrientos J, Niesvizky R, Coleman M, Leonard JP. Martin P, et al. Among authors: furman rr. Semin Hematol. 2008 Apr;45(2):126-32. doi: 10.1053/j.seminhematol.2008.02.007. Semin Hematol. 2008. PMID: 18381108 Review.

5

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.

Paoluzzi L, Gonen M, Bhagat G, Furman RR, Gardner JR, Scotto L, Gueorguiev VD, Heaney ML, Manova K, O'Connor OA. Paoluzzi L, et al. Among authors: furman rr. Blood. 2008 Oct 1;112(7):2906-16. doi: 10.1182/blood-2007-12-130781. Epub 2008 Jun 30. Blood. 2008. PMID: 18591385 Free article.

6

Outcome of deferred initial therapy in mantle-cell lymphoma.

Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, Elstrom R, Niesvizky R, Ely S, Diliberto M, Melnick A, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP. Martin P, et al. Among authors: furman rr. J Clin Oncol. 2009 Mar 10;27(8):1209-13. doi: 10.1200/JCO.2008.19.6121. Epub 2009 Feb 2. J Clin Oncol. 2009. PMID: 19188674

7

Durable complete remissions in HIV-associated Hodgkin lymphoma after treatment with only one cycle of chemotherapy complicated by sepsis.

Martin P, Leonard JP, Coleman M, Furman RR. Martin P, et al. Among authors: furman rr. Clin Lymphoma Myeloma. 2009 Jun;9(3):247-9. doi: 10.3816/CLM.2009.n.049. Clin Lymphoma Myeloma. 2009. PMID: 19525196

8

Transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma to interdigitating dendritic cell sarcoma: evidence for transdifferentiation of the lymphoma clone.

Fraser CR, Wang W, Gomez M, Zhang T, Mathew S, Furman RR, Knowles DM, Orazi A, Tam W. Fraser CR, et al. Among authors: furman rr. Am J Clin Pathol. 2009 Dec;132(6):928-39. doi: 10.1309/AJCPWQ0I0DGXBMHO. Am J Clin Pathol. 2009. PMID: 19926586

9

A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia.

Furman RR, Forero-Torres A, Shustov A, Drachman JG. Furman RR, et al. Leuk Lymphoma. 2010 Feb;51(2):228-35. doi: 10.3109/10428190903440946. Leuk Lymphoma. 2010. PMID: 20038235 Clinical Trial.

10

Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib.

Song Z, Lu P, Furman RR, Leonard JP, Martin P, Tyrell L, Lee FY, Knowles DM, Coleman M, Wang YL. Song Z, et al. Among authors: furman rr. Clin Cancer Res. 2010 Jan 15;16(2):587-99. doi: 10.1158/1078-0432.CCR-09-1519. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068106

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

182 results

Search Page